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Abstract: Development of successful clinical treatments for peripheral nerve injury is limited due to the 
complications behind neural physiology. Human mesenchymal stem cells (hMSCs) have the ability to 
directly promote tissue repair and protect cells at the injury site. Studies have shown that hMSCs can be 
transplanted to improve nerve regeneration. Hypoxic culture condition has been proven to maintain the 
stemness of hMSCs for later differentiation. In this study, we investigated the effects of low oxygen (O2) 
(2% and 5% O2) pre-treatment and initial seeding density (500, 1000, and 2000 cells/cm
2
) on glial 
protein expression during glial differentiation of hMSCs. Results showed that the secretion of glial 
proteins was tunable by modifying the seeding density. Moreover, glial induction of hMSCs, 
characterized by the glial fibrillary acidic protein (GFAP) and S100β expressing phenotype, were 
enhanced by short-term hypoxia pretreatment. The significantly increased gene expression, including 
GFAP (10 folds in 2% O2, 25 folds in 5% O2), 2’,3’-Cyclic Nucleotide 3’ Phosphodiesterase (CNP) (600 
folds in 2% O2, 800 folds in 5% O2), and neural growth factor receptor (NGFR) (4 folds in 5% O2), 
indicated that low oxygen, especially 5% O2 pretreated hMSCs had an improved potential for peripheral 
nerve regeneration. 
Keywords: mesenchymal stem cells; hypoxia; glial phenotype induction 
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1. Introduction 
A variety of trauma can lead to peripheral nerve injury. According to the statistical report from U.S. 
Department of Transportation, 2,313,000 people were injured from car accidents in 2013 [1]. In addition, 
3,701,652 people were injured from sports and recreational activities in 2014 [2]. Peripheral nerve injury 
induces endoneurial hypoxia which is attributed to fibrosis, metabolic failure, and persistent vascular 
dysfunction. After injury, a set of inflammatory activities were initiated to promote the newly recruited 
glial cells to form supporting networks for axon regeneration [3–5]. However, complete recovery from 
self-regeneration is fairly infrequent. The key to surgical repair of the transected nerve is to bridge the 
lesion with either autologous nerve graft [6], or synthetic nerve graft [7] for the local axon to rejoin. 
Advanced technologies such as a drug loaded hydrogel [8], decellularized tissue scaffold [9], and cell 
transplantation [10] have been incorporated into conduit design for nerve repair. Since the Büngner 
bands formation is critical to initiate the regeneration of axons during Wallerian degeneration, 
transplanting autologous Schwann cells to assist this process can be promising. However, robust 
harvesting and expanding Schwann cells in vitro can be challenging [11]. With the development of stem 
cell based technology, using stem cell to repair damaged neural tissues as an alternative of autologous 
Schwann cells has become more applicable [12]. 
Human mesenchymal stem cells (hMSCs) are stem cells primarily harvested from bone marrow 
and fat tissue. hMSCs are easy to obtain from adults and can be expanded rapidly in vitro to reach a 
desired number for effective therapy [13]. Besides their multi-lineage differentiation ability, hMSCs 
have the ability to directly promote tissue repair and protect cells at the injury site [14–16]. Moreover, 
hMSCs have immunoregulatory properties, which can modulate the immune system and reduce the 
extensive inflammatory response. Clinical studies suggest that transplantation of allogenic hMSCs does 
not lead to any immune rejection [17,18]. With proper induction using specific growth factors, hMSCs 
can be induced to express glial proteins [19] or neuronal proteins [20] and show morphological 
similarities. hMSCs can improve function of damaged nerves, which has been shown to be promising by 
transplanting hMSCs to the injury site [21]. Although the detailed mechanism of how hMSCs participate 
in neurological functions has not yet been fully discovered, it was suggested that the neurological 
regeneration function of hMSCs is dependent on the paracrine interaction with neighboring cells, 
including direct neuroprotective effect of the hMSCs and secretion of neurotrophic factors [22,23]. 
The bone marrow niche where hMSCs reside has physiological low oxygen (O2) partial pressure 
varies from 1% to 7% [24]. Mimicking the physiological condition for hMSCs before differentiation can 
inhibit senescence and maintain stem cell multi-potency [25]. Due to the ectodermal origin of glial cells, 
inducing hMSCs (mesodermal) into glial protein expressing cells requires superior differentiation 
potency, which means the stemness of hMSCs needs to be maintained at a high level. To achieve this, 
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using hypoxic culture along with early passage of hMSCs will be necessary [26]. Besides the effect of 
maintaining the multi-potency of hMSCs, hypoxia pre-treatment can also promote cell survival and help 
hMSCs migrate to the target site where regeneration takes place [27]. Since endoneurial hypoxia takes 
place after injury, transforming this pathological condition into a promotional effect for hMSC therapy 
would be a significant advantage. 
Cell-cell interaction plays a vital role in hMSC differentiation. For example, it has been reported 
that high seeding density is crucial for adipose-derived hMSCs to self-assemble into vascular  
structures [28]. Similarly, high cell seeding density promotes osteogenic differentiation of hMSCs, but 
has no effect on chondrogenic differentiation [29]. However, few studies were done to optimize the cell 
seeding density when inducing hMSCs into glial phenotype expressing cells. Previous studies on neural 
progenitor cells (NPC) have found that glial fibrillary acidic protein (GFAP) expression is enhanced by 
increasing the seeding density of NPCs [30]. Another study found that the expression of 2’,3’-cyclic 
nucleotide 3’ phosphodiesterase (CNP) can be reduced by increasing the seeding density of NPCs [31]. 
Thus, finding an optimized seeding density of hMSCs can be a good starting point for controllable glial 
cell phenotype modification for neural tissue engineering applications. 
The objective of this study was to investigate the effect of short term low oxygen pre-treatment and 
initial seeding density on glial induction of hMSCs. Hypoxia conditions mimicking the residential 
microenvironment of bone marrow-derived hMSCs (2% O2 and 5% O2) were adapted as pretreatment 
conditions before glial induction. Initial seeding density of 500, 1,000, and 2,000 cells/cm² were investigated. 
The expression of GFAP and S100β (Calcium-binding protein B) at both transcriptional and translational 
levels, regarding different experiment groups, were characterized.  
2. Materials and Methods 
2.1. Pre-treat hMSCs in physiologically low O2 
Bone marrow–derived hMSCs were provided by Texas A & M University Health Sciences Center. 
The cells were expanded following our published methods [32,33]. Passage 3 hMSCs were prepared for 
glial phenotype induction and cultured in basal α-Minimum Essential Medium (MEM) (Life Technology, 
Rockville, MD) supplemented with 1% L-glutamine, 1% Pen/Strep (Life Technology), and 20% Fetal 
Bovine Serum (FBS). Initial seeding density of 500, 1,000, and 2,000 cells/cm
2
 were used for seeding 
density optimization. Before glial induction, hMSCs were cultured under different O2 tension: 2%, 5%, 
and 20% (control group). The O2 level was controlled by utilizing the low O2 culture chamber 
(BioSpherix, Lacona, NY). Low O2 treatment was performed during the pre-differentiation phase, where 
hMSCs were treated with β-mercaptoethnol (Thermo Fisher Scientific, Waltham, MA) for 24 hours, 
followed by a 72-hour treatment with all-trans-retinoic acid (Sigma-Alderich, St Louis, MO). 
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2.2. Glial phenotype induction of hMSCs 
Glial induction was performed according to the method described by Brohlin M, 2009 [19]. Glial 
induction medium was made with 5 ng/mL platelet derived growth factor-AA (Sigma-Alderich),  
10 ng/mL basic fibroblast growth factor (Thermo Fisher Scientific), 5.7 µg/mL Froskolin (Abcam, 
Cambridge, MA), and 126 ng/mL glial growth factor-2 (Reprokine, Israel) supplied in α-MEM. The 
glial induction medium was added after low oxygen pre-treatment, and all culture plates were moved to 
the incubator under 20% O2. The induction medium was replaced every 72 hours. Three samples were 
prepared for each condition. 
2.3. Cell proliferation assay 
The cell proliferation under different culture conditions was evaluated by using XTT (2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) cell proliferation assay kit (ATCC, 
Manasass, VA) at day 3 and day 7 during the induction process. Cells were incubated in activated XTT 
solution for 4 hours as directed by the kit manual. Results were obtained using VersaMax ELISA 
microplate reader (Molecular Device, Sunnyvale, CA). hMSCs cultured with non-induction medium and
 
under normoxia was used as undifferentiated control. Three independent samples were tested under each 
experimental condition. 
2.4. Immunofluorescent staining and quantification 
Glial specific proteins S100β (Abcam) and GFAP (Cell Signaling Technology, Danvers, MA) 
primary antibodies were selected to identify the glial phenotype of differentiated hMSCs as they were 
widely used as indicators of glial cells by other groups. With the completion of glial induction, cells 
were fixed in 3.7% formaldehyde in phosphate buffered saline (PBS) solution (Thermo Fisher Scientific) 
for 30 minutes. Fixed cells were permeabilized in PBS (Fisher Scientific) with 0.2% Triton X-100 
(Thermo Fisher Scientific) for another 30 minutes followed by 1 hour of blocking in PBS with 1% 
bovine serum albumin (Thermo Fisher Scientific). Cells were then incubated with primary antibody 
overnight at 4 ºC followed by Alexa fluor 488 secondary antibody (Life Technology) for 40 minutes. 
DAPI (Thermo Fisher Scientific) was used to stain cell nuclei. The samples were viewed using an 
Olympus BX51 fluorescent microscope. ImageJ was used to perform fluorescent intensity analysis in 
which threshold was set to highlight the positively stained area of single cell followed by integrated 
intensity measurement. This method was adopted from Jensen EC. 2013 [34]. Blind analysis was 
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2.5. Quantitative RT-PCR analysis on expression level of glial and stem cell genes 
Table 1. Primer Design of Glial and Stem Cell Proteins. 









GFAP 5’-CTGCTCAATGTCAAGCTG 5’-GCTGGTTTCTCGAATCTG 
Calcium-binding 
protein B 




CNP 5’-ACCTACTTTGGAAAGAGACC 5’-TTAACACATCTTGTTGAGCG 
Nerve Growth 
Factor Receptor 





POU5F1 5’-GATCACCCTGGGATATACAC 5’-GCTTTGCATATCTCCTGAAG 
SRY (Sex 
Determining 
Region Y)-Box 2 
SOX2 5’-ATAATAACAATCATCGGCGG 5’-AAAAAGAGAGGCAAACTG 
Reverse transcriptional quantitative polymerase chain reaction (RT-qPCR) was used to determine 
the amount of mRNA production of glial specific proteins. RNA was extracted using RNeasy® 
extraction kit (Qiagen, Germany). Extracted RNA was reverse transcribed into cDNA using reverse 
transcription kit (Life Technology) and quantified by StepOnePlus™ real-time PCR system (Applied 
Biosystems, Waltham, MA) via SYBR® Green Real Time PCR Master Mixes (Life Technology). 
GAPDH gene was used as endogenous control for this analysis. Customized KiCqStart® SYBR® Green 
Primers (Sigma-Alderich) were used and the sequences were listed in Table 1. RNA extraction was 
performed on three independent samples from each group, and each qPCR amplification was triplicated. 
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2.6. Statistical analysis 
Results from experiments were expressed as means ± standard deviation. T-test function of Excel 
(Microsoft, Redmond, WA) was used for comparisons between groups, and statistical significance was 
accepted at p < 0.05. 
3. Results 
3.1. Proliferation of hMSCs under physiologically low O2 tension 
To assess the status of the hMSCs during the glial induction process, cell proliferation were 
evaluated by XTT assay at day 3 and day 7. At day 3, the 2,000 group (2,000 cells/cm² seeding density) 
displayed the highest proliferation rate (55% increase compared to non-induction control, as shown in 
Figure 1A.); however, it didn’t increase much from day 3 to day 7. On the contrary, the 500 group  
(500 cells/cm
2
) and 1,000 group (1,000 cells/cm
2
) showed dramatically increased cell proliferation rate 
from day 3 to day 7. When evaluating hMSCs proliferation under different O2 tensions at seeding 
density of 2,000 cells/cm
2
, the 2% O2 group had the highest proliferation rate both at day 3 and day 7 as 
shown in Figure 1B. Note that the proliferation rate of the 2% O2 group is higher (139%) than the 
undifferentiated control. Both 5% O2 group and 20% O2 group have a slight increase in proliferation 
from day 3 to day 7.  
 
Figure 1. XTT proliferation assay of glial induced hMSCs. (A) Proliferation of cells in 
groups with different initial seeding density. Note that proliferation of lower initial cell 
seeding density groups started with lower proliferation then increased dramatically after 7 
days. (B) Proliferation of cells in groups with different O2 concentration. Note that 2% O2 
group has higher proliferation after 7 days compared to the 20 % O2 control group. 
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3.2. Expression of GFAP and S100β protein during glial phenotype induction 
 
Figure 2. Expression of GFAP and S100β on untreated hMSCs and glial induced 
hMSCs (2000 cells/cm², 20% O2). (A) Immunofluorescent staining of GFAP and S100β 
in undifferentiated control and glial differentiated group. (B) Quantitative fluorescent 
analysis of GFAP and S100β. Significant differences were found between undifferentiated 
and glial differentiated hMSCs on both GFAP and S100β expression. * p < 0.01. 
Immunofluorescent staining of GFAP and S100β were done after 3 days of culture in glial 
induction medium under the 20% O2 condition. hMSCs cultured under the same condition in normal 
culture medium were used as control. There was weak expression of GFAP and S100β in the 
undifferentiated control, but both GFAP and S100β proteins were gathered around the nuclei, as shown 
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in Figure 2A. In the differentiated group, the expression of GFAP and S100β was higher in intensity, 
and both GFAP and S100β expression are more spread into cytoplasm than undifferentiated control. 
Quantitative fluorescent intensity analysis demonstrated that GFAP and S100β expression in glial 
differentiated group was approximately 3 folds higher than non-differentiated group (p < 0.01), as 
shown in Figure 2B. 
3.3. Influence of initial seeding density on glial induction of hMSCs 
 
Figure 3. Glial protein expression of glial induced hMSCs with different cell seeding densities 
from day 3 to day 7. (A) Immunofluorescent staining of GFAP and S100β at day 3 and day 7. (B) 
Quantitative fluorescent analysis of GFAP and S100β. Note that S100β expression in 2000 
cells/cm² group was significantly higher than all other groups at day 7. * p < 0.05, ** p < 0.01. 
After showing that hMSCs can be successfully induced to express glial proteins, the influence of 
different seeding densities on glial protein expression after the induction was investigated. Initial 
seeding densities of 500, 1,000, and 2,000 cells/cm
2
 were employed before the pre-treatment process. 
Cells in all cultures were positively stained for GFAP and S100β (Figure 3A). Quantitative fluorescent 
analysis showed that significant differences were found between 500 and 1,000 group (p < 0.01) at day 3, 
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and between 500 and 2,000 group (p < 0.05) at day 7 for GFAP expression. For S100β expression, 
significant differences were found between 500 and 1,000 group (p < 0.01) at day 3, and 2,000 group is 
significantly higher (p < 0.05) at day 7 (Figure 3B). 
 
Figure 4. Quantitative RT-PCR analysis on glial phenotype induced hMSCs with different 
seeding densities from day 3 to day 7. At day 3, the mRNA production of GFAP, S100β, and 
CNP levels were low while the NGFR level was high in all groups. At day 7, the expression 
level of GFAP and S100β, CNP and NGFR had significantly increased. * p < 0.01. 
The expression of glial and stemness genes was further quantified using RT-qPCR. At day 3, the 
mRNA production of GFAP, S100β, and CNP levels were very low; however, the neural growth factor 
receptor (NGFR) mRNA production level was high in all groups: with 2.5 fold increase in 500 group, 7.5 
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folds increase in 1,000 group, and 5 folds increase in 2,000 group. Furthermore, NGFR production in the 
1,000 group was significantly higher than the other two groups. The stem cell gene Oct-4 had the lowest 
expression in the 2,000 group at day 3, while another stemness gene protein Rex-1 expression was at 
minimum low level. At day 7, the expression level of GFAP and S100β significantly increased. Moreover, 
the expression level of CNP in the 500 group was higher than other groups. The expression level of NGFR 
was also higher in the 500 group at day 7. From day 3 to day 7, Expression of stem cell gene Oct-4 was 
slightly lower in the 1,000 and 2,000 groups, and slightly increased in the 500 group from day 3 to day 7. 
The expression of Rex-1 was slightly increased in the 500 group and 2,000 group (Figure 4). 
3.4. Effect of hypoxia pretreatment on glial induction of hMSCs 
 
Figure 5. Glial protein expression of glial induced hMSCs pre-conditioned with different O2 
from day 3 to day 7. (A) Immunofluorescent staining of GFAP and S100β at day 3 and day 7.  
(B) Quantitative fluorescent analysis of GFAP and S100β. Note that GFAP expression was 
significantly lowered by 2% O2 but increased by 5% O2 group; at day 7, while S100β expression was 
lowered by both 2% and 5% O2 group. * p < 0.05, ** p < 0.01. 
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Figure 6. Quantitative RT-PCR analysis on glial induced hMSCs pre-conditioned with 
different O2 tensions from day 3 to day 7. Note that the expression of GFAP, S100β, and CNP 
was kept at lower level at day 3. At day 7, GFAP, CNP, and Rex-1 expression increased in 2% and 
5% O2 groups compared to 20% group. * p < 0.01. 
To mimic the native growth environment of bone marrow derived hMSCs, 2% and 5% O2 tension 
were used to pre-treat hMSCs before glial induction. Immunofluorescent staining and quantification in 
Figure 5 indicated that the expressions of GFAP and S100β were kept at lower levels. For GFAP 
expression, significant differences were found between 5% and 20% O2 groups (p < 0.05) at day 3, and 2% 
O2 group was significantly lower in expression (p < 0.01) at day 7. For S100β expression, 2% O2 group 
was significantly lower (p < 0.01) at day 3, and 20% O2 group showed significantly higher expression  
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(p < 0.01) at day 7. Quantitative RT-PCR results were consistent with the observed increase with GFAP 
and S100β expression from the immunofluorescent staining in all groups. The expression of CNP was 
dramatically higher in 2% O2 (600 folds higher) and 5% O2 (800 folds higher) groups than 20% group. 
NGFR expression was the highest in the 5% O2 group for both day 3 and day 7 compared to other 
groups. The 2% O2 group had lower NGFR expression than the 5% O2 group, but higher than the 20% 
O2 group. The stem cell gene Rex-1 expression was higher in 2% and 5% O2 groups at day 7 compared 
to the 20% O2 group. However, the Oct-4 expression was dramatically decreased after 7 days for all 
groups (Figure 6). 
4. Discussion 
It has been confirmed that hMSCs can be transplanted to accelerate the regeneration of peripheral 
nerve after injury in vivo [35]. However, the debates about whether or not the glial induction of hMSCs 
is necessary to achieve neurological regeneration (full-functional recovery) remains unsolved. It has 
been reported that transplantation of undifferentiated hMSCs had success to accelerate regeneration in 
rat sciatic nerve. Nevertheless, it was indicated that potential differentiation process was triggered by the 
local microenvironment after transplantation [23]. Another study demonstrated that undifferentiated 
hMSCs had impaired regeneration results while glial differentiated hMSCs had comparable results with 
Schwann cells [21]. These results indicated that differentiation of hMSCs may promote peripheral nerve 
regeneration more efficiently than undifferentiated hMSCs. It is critical to understand how the glial 
induction of hMSCs is affected by different cell culture conditions. Here we conducted a preliminary 
study to assess the ability of hMSCs to express glial proteins as the result of a glial induction protocol. 
Since there were none well-establish protocols being published by any group, we have tried to tune the 
culture condition of the hMSCs to optimize the adapted protocol. In this study, the oxygen concentration 
was tuned to examine its effect on the glial induction of hMSCs. Physiologically low O2 is a factor that 
has drastic influence on cell survival and regeneration effectiveness; moreover, low O2 culture can be 
used to better mimic the native microenvironment of peripheral nerves after injury [4]. Studying how 
hypoxia pre-treatment affects glial phenotype expression of hMSCs can help to provide better 
understanding of hMSCs based peripheral nerve regeneration therapy. Beside the peripheral glial marker 
expression, we also attempted to explore central nervous glial marker expression to investigate the 
potential of tuning hMSCs for central nervous system repair. Beyond hypoxic preconditioning, hMSC 
differentiation is also affected by cell seeding density as shown in studies of osteogenic, adipogenic and 
chondrogenic lineage differentiation [28,29]. Seeding density also has critical effect on the 
differentiation cascade of NPCs [30]. Examining how seeding density affects the amount of different 
glial protein expression is valuable to customize the property of glial phenotype expressing hMSCs for 
different applications.  
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Short term hypoxia exposure of hMSCs is known to maintain stem cell progenicity, improve cell 
proliferation, and increase extracellular matrix secretion [36]. To develop an efficient therapy for 
peripheral nerve regeneration, it is crucial to monitor how the hMSC glial phenotypical proteins would 
change when the cells are pre-conditioned under the hypoxia condition. During developmental stage, 
GFAP is expressed in neural progenitor cells differentiating towards astrocytes. When the progenitor 
cells are differentiated, they express high level of S100β, corresponding to the phenotype change from 
progenitor cells to mature astrocytes [37]. Studies have shown that GFAP expression was enhanced in 
astrocytes after hypoxic injury, and the elevated expression of GFAP could promote the tissue 
regeneration [38,39]. In addition, GFAP is essential for Schwann cell proliferation and lack of GFAP 
expression will cause delayed peripheral nerve regeneration [40]. In this study, we first verified that the 
GFAP and S100β protein level could be upregulated by 3-day induction under this protocol (Figure 2). 
The 2% and 5% O2 tensions were used before the hMSC induction to mimic the native bone marrow 
microenvironment, and also the pathological endoneurial hypoxia condition. low O2 (both 2% and 5% O2) 
pretreatment significantly increased GFAP expression after 7 days of induction, compared to normoxia 
(20% O2) pretreatment (Figure 6). However, S100β expression was lowered by hypoxia (Figure 5), 
suggesting that hypoxic condition did not promote the differentiation of GFAP-expressing cells into 
mature astrocytes [37]. Other than these two markers, CNP and NGFR (p75NTR) are also important 
glial markers reflecting the functional phenotype of differentiated glial cells. CNP is an important 
myelination associated structure protein during neural tissue regeneration in the central nervous  
system [41]. NGFR is the receptor of neural growth factor, which can increase the pro-healing capacity 
of NGF [42]. In addition, the NGFR is critical for motor function recovery during the remyelination 
process of the regenerated axons [43]. Elevation of CNP and NGFR are enhanced by hypoxia, 
suggesting that hypoxia could potentially assist in peripheral nerve fiber regeneration, and may be 
capable to benefit hMSC based central nervous system repair. It has been reported that hypoxia culture 
preserves the progenicity of hMSCs, which can be reflected by the expression level change of Oct-4 and 
Rex-1. Study has shown that continuous hypoxia (3% O2) culture of hMSCs resulted that the expression 
of Rex-1 (self-renewal associated gene) was not increased, as Oct-4 was significantly increased [44]. In 
our study, we found that non-continuous hypoxia treatment could increase the Rex-1 expression but not 
the Oct-4 expression (Figure 6). This discovery can be possibly related to the mechanism of how hMSCs 
respond to different duration of oxidative stress [45]. On the other hand, maintaining the glial phenotype 
of differentiated hMSCs can be challenging due to suppression of S100β after hypoxia exposure, 
prohibiting the differentiation of stem cells. Nonetheless, this study suggested that the hypoxia 
preconditioning promotes hMSCs to demonstrate peripheral glial cell phenotype instead of astrocyte 
phenotypes, which could potentially take advantage of post-injury endoneurial hypoxia as an 
enhancement of hMSC transplantation to assist peripheral nerve regeneration. The effect of hMSCs on 
peripheral nerve regeneration needs to be further examined by seeding dorsal root ganglia (DRG) cells 
in vitro or using an animal peripheral nerve injury model in vivo. A modeling system of 3-D nerve 
structure similar to the one Phillips, J. B. described [46] can be used to test that how DRG migration is 
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changed under hypoxia and if this change can be reversed by introducing hMSCs as a therapeutic cue 
for DRG regeneration. In conclusion, the hypoxia preconditioning was proved to create the suitable 
microenvironment for peripheral glial phenotype induction of hMSCs. 
Cell-cell interaction plays a vital part on proliferation and differentiation of most stem cell types 
especially in neurogenic differentiation [47]. We studied how the initial seeding density difference could 
affect expression of glial proteins such as GFAP and S100β in glial-induced hMSCs (Figure 3). Higher 
GFAP and S100β expression was observed at day 7 in 1,000 and 2,000 groups (Figure 4). A similar 
trend was observed by Ashton et al., who discovered that GFAP expression was proportional to NPC 
seeding density [30], suggesting that the communication between the differentiating hMSCs (similar to 
NPCs) is important for GFAP transcription. CNP expression was dramatically increased at day 7 in the 
500 group from our results (Figure 4), and the Wernicke group had observed similar activity where CNP 
activity was the highest when initial seeding density was the lowest [31]. This result suggested that 
under current induction protocol, oligodendrocyte induction of hMSCs was favorable under low seeding 
density, which enhances the potential of oligodendrocyte-like cells for central nervous system 
applications. In conclusion, different glial protein expression was tunable by modifying initial seeding 
density, which enabled the potential of creating customizable hMSCs based regeneration therapy for 
both peripheral and central nervous system injuries. 
5. Conclusions 
hMSCs have been extensively used in regeneration therapy designs. For peripheral nerve 
regeneration, direct hMSCs transplantation has been examined as a therapeutic application. Our study 
demonstrated that the glial induction of hMSCs was enhanced by hypoxia pre-treatment, with mRNA 
expression profile changed towards peripheral glial phenotypes. Higher initial seeding density was 
required for hMSCs to express peripheral glial proteins in vitro, while lower initial seeding density 
promotes oligodendrocyte phenotype induction. These results suggested that optimization of the glial 
induction culture conditions of hMSCs led to the control of different glial phenotype induction. In 
summary, this study paved the preliminary understanding of how hMSCs respond to different 
microenvironment, which was critical to design better hMSC based neural regeneration therapy. 
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